Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Female | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-081 | 512-56-1 | Trimethylphosphate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-201 | 1746-01-6 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | Mice | Swiss Webster | Female | Topical Application | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 2/41 8/27 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 0/50 5/50 11/50 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50 | Neoplastic Lesions |
| Yes | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Female | Dosed-Feed | Subcutaneous Tissue | Positive | Equivocal Evidence | FIBROMA 0/56 2/56 1/56 4/56; FIBROSARCOMA 1/56 0/56 1/56 3/56 | May Have Been Related |
| Yes | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Equivocal Evidence | FIBROMA 0/56 1/56 2/56 4/56; FIBROSARCOMA 0/56 1/56 0/56 1/56 | May Have Been Related |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 0/50 15/50 10/50 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/50 20/50 16/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| Yes | TR-341 | 67-20-9 | Nitrofurantoin | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Some Evidence | Equivocal Evidence | FIBROMA 0/50 5/50 4/50; FIBROSARCOMA 1/50 2/50 1/50 | May Have Been Related |
| Yes | TR-359 | 298-81-7 | 8-Methoxypsoralen | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | FIBROMA 1/50 5/50 7/49 | May Have Been Related |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 11/50 11/50 18/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 7/49 13/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/49 5/49 37/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Male | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/41 0/48 11/46; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/41 3/48 19/46 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 1/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/48 4/47 COMBINED 0/50 0/48 5/47 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Positive | Positive | ADENOCARCINOMA 2/50 14/50 8/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Positive | Positive | FIBROADENOMA 4/50 29/50 24/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 7/50 25/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Nasal Cavity | Positive | Positive | CARCINOMA 0/50 0/50 6/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 3/50; ADENOCARCINOMA 0/50 20/50 29/50; CARCINOMA 0/50 0/50 25/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 0/50; ADENOCARCINOMA 0/50 20/50 28/50; CARCINOMA 0/50 0/50 21/50 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 0/50 5/50 11/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 11/50 23/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 1/50 15/50 | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (POLYP, SARCOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Vascular System (Unspecified) | Positive | Positive | (HEMANGIOSARCOMA) | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
| No | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE OR CARCINOMA) | Neoplastic Lesions |
| No | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Female | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-029 | 129-15-7 | 2-Methyl-1-nitroanthraquinone | Mice | B6C3F1 | Male | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| No | TR-201 | 1746-01-6 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | Mice | Swiss Webster | Male | Topical Application | Subcutaneous Tissue | Equivocal Evidence | Equivocal | FIBROSARCOMA 3/42 6/28 | Neoplastic Lesions |
| Yes | TR-201 | 1746-01-6 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | Mice | Swiss Webster | Female | Topical Application | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 2/41 8/27 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Liver | Positive | Positive | ADENOMA 2/50 3/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Liver | Positive | Positive | NEOPLASTIC NODULE 3/50 8/50 8/48 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Mammary Gland | Positive | Positive | FIBROADENOMA 15/50 21/50 18/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Positive | Positive | ADENOMA 1/47 3/47 7/49 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Pancreas Islet Cell | Positive | Positive | ADENOMA 0/50 6/49 2/47 CARCINOMA 0/50 1/49 0/47 COMBINED 0/50 7/49 2/47 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Vascular System (Unspecified) | Positive | Positive | HEMANGIOMA 0/50 1/50 2/50 OR HEMANGIOSARCOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Female | Dosed-Feed | Liver | Positive | Equivocal Evidence | NEOPLASTIC NODULE 0/56 1/56 2/56 4/56 | May Have Been Related |
| No | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Female | Dosed-Feed | Nasal Cavity | Positive | Positive | ADENOMA 0/56 0/56 1/56 6/56; CARCINOMA 0/56 0/56 1/56 24/56 | Neoplastic Lesions |
| No | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Male | Dosed-Feed | Nasal Cavity | Positive | Positive | ADENOMA 0/56 0/56 2/56 10/56; CARCINOMA 0/56 0/56 0/56 26/56 | Neoplastic Lesions |
| Yes | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Female | Dosed-Feed | Subcutaneous Tissue | Positive | Equivocal Evidence | FIBROMA 0/56 2/56 1/56 4/56; FIBROSARCOMA 1/56 0/56 1/56 3/56 | May Have Been Related |
| Yes | TR-278 | 87-62-7 | 2,6-Xylidine | Rats | CD | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Equivocal Evidence | FIBROMA 0/56 1/56 2/56 4/56; FIBROSARCOMA 0/56 1/56 0/56 1/56 | May Have Been Related |
| No | TR-359 | 298-81-7 | 8-Methoxypsoralen | Rats | F344/N | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-359 | 298-81-7 | 8-Methoxypsoralen | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/50 11/50 8/49 OR ADENOCARCINOMA 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-359 | 298-81-7 | 8-Methoxypsoralen | Rats | F344/N | Male | Gavage | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 9/50 9/49 | May Have Been Related |
| Yes | TR-359 | 298-81-7 | 8-Methoxypsoralen | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | FIBROMA 1/50 5/50 7/49 | May Have Been Related |